Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register.
Evangelou N, Garjani A, dasNair R, Hunter R, Tuite-Dalton KA, Craig EM, Rodgers WJ, Coles A, Dobson R, Duddy M, Ford DV, Hughes S, Pearson O, Middleton LA, Rog D, Tallantyre EC, Friede T, Middleton RM, Nicholas R. Evangelou N, et al. Among authors: hughes s. J Neurol Neurosurg Psychiatry. 2020 Aug 27;92(1):107-9. doi: 10.1136/jnnp-2020-324449. Online ahead of print. J Neurol Neurosurg Psychiatry. 2020. PMID: 32855290 Free PMC article. No abstract available.
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies.
Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, Coles A, Dobson R, Duddy M, Hughes S, Pearson OR, Rog D, Tallantyre EC, das Nair R, Nicholas R, Evangelou N. Garjani A, et al. Among authors: hughes s. Mult Scler Relat Disord. 2021 Jul;52:102939. doi: 10.1016/j.msard.2021.102939. Epub 2021 May 5. Mult Scler Relat Disord. 2021. PMID: 34010764 Free PMC article.
Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register.
Garjani A, Hunter R, Law GR, Middleton RM, Tuite-Dalton KA, Dobson R, Ford DV, Hughes S, Pearson OR, Rog D, Tallantyre EC, Nicholas R, Morriss R, Evangelou N, das Nair R. Garjani A, et al. Among authors: hughes s. Mult Scler. 2022 Jun;28(7):1060-1071. doi: 10.1177/13524585211020435. Epub 2021 Jun 3. Mult Scler. 2022. PMID: 34080892
Developing evidence-based guidelines for the safety of symptomatic drugs in multiple sclerosis during pregnancy and breastfeeding: A systematic review and Delphi consensus.
Iyer P, Wiles K, Ismail A, Nanda S, Murray K, Hughes S, Ford HL, Pearson OR, White S, Bonham N, Hoyle N, Witts J, Middleton R, Brex PA, Rog D, Dobson R. Iyer P, et al. Among authors: hughes s. Mult Scler. 2023 Mar;29(3):395-406. doi: 10.1177/13524585221148094. Epub 2023 Feb 5. Mult Scler. 2023. PMID: 36740816
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Braisher M, Blackstone J, Ciccarelli O, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Eur J Neurol. 2023 Sep;30(9):2769-2780. doi: 10.1111/ene.15924. Epub 2023 Jun 23. Eur J Neurol. 2023. PMID: 37318885 Clinical Trial.
Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC, Dobson R, Froud JLJ, St John FA, Anderson VM, Arun T, Buckley L, Evangelou N, Ford HL, Galea I, George S, Gray OM, Hibbert AM, Hu M, Hughes SE, Ingram G, Kalra S, Lim CE, Mathews JTM, McDonnell GV, Mescall N, Norris S, Ramsay SJ, Rice CM, Russell MJ, Shawe-Taylor MJ, Williams TE, Harding KE, Robertson NP. Tallantyre EC, et al. Among authors: hughes se. Eur J Neurol. 2024 Jul;31(7):e16289. doi: 10.1111/ene.16289. Epub 2024 Apr 3. Eur J Neurol. 2024. PMID: 38567516 Free PMC article.
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: hughes s. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T; MSBase Study Group. He A, et al. JAMA Neurol. 2015 Apr;72(4):405-13. doi: 10.1001/jamaneurol.2014.4147. JAMA Neurol. 2015. PMID: 25665031 Free article.
3,731 results